Dahl Andrew M. 4

What Happened

• Andrew M. Dahl, SVP & Corporate Controller at Edwards Lifesciences (EW), received equity awards on May 7, 2026: 3,985 shares (RSUs), 3,020 shares (RSUs), and a derivative award of 6,745 option shares (total 13,750). Grants were reported at $0.00 per share.
• On May 8, 2026, 289 shares were disposed at $82.76 per share for total proceeds of $23,918 to satisfy tax withholding or payment of exercise price/tax liability related to the awards. This was a withholding-type disposition rather than an open-market sale.

Key Details

• Transaction dates: Grants on 2026-05-07; withholding/disposition on 2026-05-08.
• Prices/values: Grants reported at $0.00; 289 shares disposed at $82.76 each for $23,918.
• Shares acquired: 13,750 total (3,985 + 3,020 awarded RSUs; 6,745 option/derivative units).
• Shares disposed: 289 withheld/surrendered to cover tax liability (code F — tax withholding).
• Vesting: Footnotes state RSUs and options vest in four equal annual installments beginning one year after grant (standard multi-year vesting).
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filed 2026-05-08 for transactions dated 2026-05-07/08 — appears timely.
• Additional note: Filing remarks mention inclusion of routine quarterly Employee Stock Purchase Plan acquisitions.

Context

• The main activity is a typical executive equity grant (RSUs and options) with a small number of shares surrendered to cover taxes. Such withholding transactions are common when awards vest or are granted and do not necessarily indicate a change in insider sentiment.
• The derivative line refers to option awards; these options will vest over time per the stated schedule and are not exercised in full here. The 289-share disposition was used for tax obligations, not an open-market sale.